TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged ≥18 years~2. Histologically proven adenocarcinoma of the colon;~3. Completed cancer staging with CT-abdomen and CT-thorax/X-thorax according to hospital's standard of care;~4. Confirmed eligibility for surgery with curative intent as deemed by the hospital's multidisciplinary board (MDB) review;~5. An intratumoural gene expression profile of PDGFR-α, PDGFR-β, PDGF-C and KIT, indicative of the mesenchymal phenotype, according to our diagnostic RT-qPCR test (i.e. more than 50% chance of having the mesenchymal phenotype);~6. Minimum of four properly stored pre-treatment biopsies for gene expression analysis/ELISA;~7. WHO performance status 0 or 1;~8. Adequate haematology status and organ function, defined as:~   * Normal creatinine clearance (≥60 ml/min (MRDR))~  * ALAT within 2.5x upper limit of normal (ULN)~  * PT-INR \< 1.5~  * Leukocytes \> 1,5\*10\^9/L; Hb \> 6.0 mmol/L; platelets \> 100\*10\^9/L~9. Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests;~10. Written informed consent.~Exclusion Criteria:~1. The presence of synchronous distant metastases;~2. Current hospital standard of care dictates that subject should undergo any neoadjuvant therapy;~3. Concurrent participation in another clinical trial using any medicinal product, or participation in such a trial in the period of three months prior to the current trial;~4. Women who are pregnant, plan to become pregnant or are lactating during the study or for up to 30 days after the last dose of imatinib;~5. Known HIV or Hepatitis B/C infection;~6. Known symptomatic congestive heart failure;~7. Co-morbidity requiring concomitant treatment with drugs that act as strong inducers of CYP3A4 or with drugs with a narrow therapeutic range influenced by imatinib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bedside Therapeutic Monitoring of β-Lactam Levels in Newborns, Children and Adolescents Admitted to Intensive Care.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age younger than 18 years~* Newborns (preterm or not) in neonatal intensive care~* Infants, children, and adolescents in pediatric intensive care~* Clinically suspected or microbiologically proven sepsis that might be associated with ventilator-associated pneumonia or otherwise associated with health care~* Need for antibiotic treatment by piperacillin-tazobactam, ceftazidime, or meropenem of intermittent administration~* Informed consent form signed by parents/guardian~* Informed consent form signed by patients old enough to understand.~Exclusion Criteria:~* Process for active limitation of treatment underway~* Suspected or known hypersensitivity to studied beta-lactams~* Renal failure, defined as serum creatinine \> 1.5 mg/dl or urine production \< 0.3 ml/kg for 24 h or anuria for 12 h.~* Co-administration of two β-lactam antibiotics~* Cystic fibrosis~* No national health insurance coverage in French center~* Family unable to understand study-related information due to language or other communication issues~* No consent obtained

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- pharmacokinetic device (Type: EXPERIMENTAL): MON4STRAT system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: rTMS Combined With BWSTT in Stroke With Body Weight Supported Treadmill Training (BWSTT) After Stroke

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-80 years old~2. \< 2 months post stroke at the time of enrollment~3. first time stroke:~4. able to walk \> 25 feet with or without assistive device and with no more than moderate assistance:~5. able to follow 1-step commands~6. able to communicate verbally~Exclusion Criteria:~1. severe medical problems (e.g. recent cardiac infarct, heart failure, cancer)~2. presence of conditions that could affect gait training (e.g. amputation, severe arthritis)~3. bilateral stroke~4. non-ambulatory prior to stroke~5. BMI \> 40~6. any contraindications to TMS (e.g. history of seizure, cardiac pacemaker, metal or magnetic implants)~7. pregnant or potentially to be pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- High Frequency rTMS (Type: EXPERIMENTAL): The High Frequency rTMS group will receive real repetitive transcranial magnetic stimulation (rTMS) in 5Hz at 90% of resting motor threshold delivered to the bilateral motor areas via a figure of 8 air-filmed coil. The stimulation is structured as 24 10-second trains with a inter-train interval of 30 second.
- Sham rTMS (Type: SHAM_COMPARATOR): The Sham rTMS group will receive the same protocol but delivered via a sham coil which generates the same auditory and cutaneous feedback as the real stimulation. However, there will be no active stimulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria Includes:~* Drusen \> 63 mm~* Choroidal neovascularization under the fovea (Predominantly Classic, Minimally Classic, and Occult lesions acceptable)~* Greatest linear dimension (GLD) of entire lesion \< 5400 µm (no reading center confirmation required)~* ETDRS best corrected visual acuity of 20/40 - 20/320 (73 - 24 letter score)~* Total area of lesion must \< 9 MPS DA~* 0-3 intravitreal injections of anti-VEGF monotherapy within 6 months of randomization with continuing evidence of exudative activity confirmed by FA or OCT within 4-8 weeks after the last injection~Exclusion Criteria Includes:~* Oral steroid use within 6 months~* Prior complications from steroid therapy~* Prior stroke, myocardial infarction, or end-stage malignancy~Study Eye Exclusion Criteria~* Geographic atrophy or fibrosis under the fovea~* Fibrosis, hemorrhage, pigment epithelial detachments and other hypofluorescent lesions obscuring more than 50% of total lesion~* Prior treatment with verteporfin within 12 months~* IOP is \>25 mmHg and the participant is on Cosopt~* Intraocular surgery within 6 weeks~* Prior vitrectomy~* Peribulbar steroid injection within 6 months~* Poor reactions to topical or periocular steroid treatment including elevated IOP

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measuring the Metabolic Cost of Fever

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- all children on the paediatric intensive care unit at Great Ormond Street Hospital who~1. are likely to or have developed a fever (suspected infection, following trauma, post major surgery)~2. are over 10kg (approx 1 year of age)~3. are invasively ventilated~Exclusion Criteria:~- Children who~1. have a brain injury, where active temperature control may be instituted~2. patients post cardiac surgery~3. patient with or at risk of cardiac arrhythmias~4. patients post cardiac arrest~5. patient with refractory status epilepticus~6. children with a greater than 5% leak around the endotracheal tube~7. children with a fraction of inspired oxygen \>0.6

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Febrile critically ill children (Type: None): Children above 10kg admitted to the paediatric intensive care unit at Great Ormond Street Hospital who are mechanically ventilated and have a high likelihood of developing a fever. Energy expenditure will be measured using indirect calorimetry at baseline, and continuously during fever, until fever subsides.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real Life

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Suffering from active disease of UC or CD according to the investigator's judgment.~2. In failure or intolerant to a previous biologic treatment, or with contra-indication to anti-TNFalpha after failure of conventional treatments, regardless of the line of treatment.~3. Meeting the same criteria as those described at the pre-screening.~4. Prescription of vedolizumab during consultation.~5. Able to be followed a priori over a period of 24 months.~Exclusion Criteria:~1. With exclusion criteria for vedolizumab and any contra-indication to vedolizumab: hypersensitivity to the active substance or to any of its excipients, active severe infections, such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections such as progressive multifocal leukoencephalopathy (PML).~2. Participation in an interventional study (but not in another non-interventional study).~3. Unclassified colitis.~4. Stomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vedolizumab (Type: None): Participants diagnosed with UC or CD, who fail or are intolerant to a previous biologic treatment or with contra-indication to anti-tumor necrosis factor alpha (TNF alpha) after failure of conventional treatments without exclusion except participant refusal, and were potentially eligible for a treatment with vedolizumab will be observed from the first prescription during consultation over a period of 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed brain tumors, including any of the following:~  * Brain stem glioma~ * Primitive neuroectodermal tumor~ * CNS germ cell tumor~ * Malignant glioma~* Diagnosis based on any of the following:~  * CT-assisted or stereotactic biopsy~ * Open biopsy~ * Surgical resection~ * Cerebrospinal fluid cytology~ * Elevated tumor markers~ * Unequivocal radiographic changes (for patients with brain stem glioma or optic glioma)~* All tumor types, except brain stem glioma, must be recurrent~* No radiographic signs of intracranial herniation and/or spinal cord block~PATIENT CHARACTERISTICS:~Performance status~* ECOG 0-2~Life expectancy~* At least 90 days~Hematopoietic~* WBC ≥ 2,500/mm\^3~* Absolute granulocyte count ≥ 1,200/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* SGOT and SGPT \< 2.5 times upper limit of normal~* Bilirubin \< 2.0 mg/dL~Renal~* Creatinine \< 1.8 mg/dL~Pulmonary~* No history of clinically significant reactive airway disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No significant risk for general anesthesia~* No uncontrolled, clinically significant, confounding medical condition within the past 30 days~* No contraindication to study drugs~PRIOR CONCURRENT THERAPY:~Chemotherapy~* At least 28 days since prior systemic chemotherapy~Radiotherapy~* At least 3 months since prior total spine radiotherapy~* At least 14 days since prior cranial radiotherapy~* Prior systemic radiotherapy allowed~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal (GE) junction~  * No T1-2, N0, M0 disease~ * No palpable or biopsy-proven involvement of supraclavicular nodes or radiographically involved supraclavicular nodes (\> 1.5 cm in greatest dimension) for lesions in mid-thoracic, distal thoracic, or GE junction~    + Supraclavicular node involvement allowed provided there are upper thoracic esophagus primary lesions~ * Patients with involvement of celiac nodes (stations 15-20) are eligible if the primary lesion is mid-thoracic, distal esophagus, or GE junction~ * No evidence of distant metastases~* Tumor must be considered surgically resectable~  - Patients with T4, N0 tumors that are potentially resectable are eligible~* No clinically relevant pleural or peritoneal effusion that is not amenable to drainage~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Life expectancy ≥ 12 weeks~* Absolute neutrophil count ≥1,500/mm\^3~* Platelet count ≥100,000/mm\^3~* Hemoglobin ≥10 g/dL~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST ≤ 3 times ULN~* Creatinine clearance ≥ 45 mL/min~* No New York Heart Association class III or IV congestive heart failure~* Pregnant or nursing women are ineligible~* Negative pregnancy test~* Fertile patients must use effective contraception~* No uncontrolled infection~* No other severe underlying disease that would preclude study entry~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ~* No prior sensitivity or allergic reaction to pemetrexed disodium or carboplatin~* Able to swallow pills~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy for esophageal cancer~* No prior radiotherapy field that overlapped the anticipated fields of study radiotherapy~* No prior radiotherapy to \> 30% of the marrow cavity~* Patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) must be able to discontinue use 2 days prior, during, and 2 days after pemetrexed disodium administration (5 days prior for long-life NSAIDs)~* Patients must not have been receiving cyclooxygenase-2 inhibitors at study entry and while receiving protocol therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed/Carboplatin (Type: EXPERIMENTAL): Pemetrexed+Carboplatin+Radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Normobaric Oxygen Therapy in Acute Ischemic Stroke Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years.~* Acute ischemic stroke in whom treatment can potentially be started within 9 hours after symptom onset. If the symptom onset time is unknown, the time of onset will be defined as the midpoint between the time when the subject was last seen neurologically intact, and when found to have a neurological deficit.~* National Institutes of Health Stroke Scale (NIHSS) score 4 or greater.~Exclusion Criteria:~* Patients being actively considered for intravenous or intra-arterial thrombolysis will be excluded.~* Patients likely to have acute stroke intervention such as carotid endarterectomy or stent or angioplasty, hemicraniectomy, etc.~* Rapidly improving neurological deficits (transient ischemic attack).~* Known history of severe chronic obstructive pulmonary disease (Forced Expiratory Vital Capacity less than 1.0 or oxygen dependent).~* More than 3 L/min oxygen required to maintain peripheral arterial oxygen saturation above 92%.~* New York Heart Association Class III heart failure.~* Endotracheal intubation prior to enrollment or impending need for artificial ventilation.~* Coma (National Institutes of Health Stroke Scale item 1a score of 3).~* Suspected seizure at or after onset of stroke, or a known active seizure disorder.~* Blood glucose below 50 mg/dL or greater than 250 mg/dL prior to enrollment.~* Concurrent severe non-stroke medical illness requiring admission to a non-neurological intensive care unit~* Expected survival less than 90 days.~* Any condition that might limit neurological assessment or follow-up in the opinion of the investigator.~* Pre-menopausal women with a positive pregnancy blood test performed at admission.~* Inability to obtain consent from the patient or legally authorized representative.~* Active participation in another intervention study (e.g. investigational drug trial).~* Proven alternate etiology for stroke-like symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NBO (Normobaric Oxygen) (Type: ACTIVE_COMPARATOR): Oxygen, inhaled at 30-45L/min via a facemask for 8 hours
- Room Air (Type: PLACEBO_COMPARATOR): Room Air, inhaled at 30-45L/min via a facemask for 8 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* KRAS and NRAS wild type metastatic colorectal cancer~* Progression following treatment for colorectal cancer with irinotecan, oxaliplatin and fluoropyrimidine therapy in the metastatic setting.~* Eastern Cooperative Oncology Group \[ECOG\] Performance Status of 0, 1, or 2~* At least one measurable lesion by Response Evaluation Criterion in Solid Tumors \[RECIST\]~Exclusion Criteria:~* More than 2 prior cytotoxic chemotherapy regimens for metastatic colorectal cancer.~* Prior treatment with a PI3K, mTOR, AKT or EGFR inhibitor~* Patients who have discontinued treatment with prior irinotecan therapy due to toxicity.~* Prior radiation to the pelvis or abdomen~* Patients with history of interstitial lung disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): PF-05212384 plus Irinotecan
- Arm B (Type: ACTIVE_COMPARATOR): Cetuximab plus Irinotecan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues